Browse > Article
http://dx.doi.org/10.12701/yujm.2021.01039

Idiopathic multicentric Castleman disease presenting progressive reticular honeycomb infiltration of lung and immunoglobulin G and immunoglobulin G4 dominant hypergammaglobulinemia: a case report  

Kim, Hyun-Je (Division of Rheumatology, Department of Internal Medicine, CHA Gumi Medical Center, CHA University)
Hong, Young-Hoon (Division of Rheumatology, Department of Internal Medicine, Yeungnam University College of Medicine)
Publication Information
Journal of Yeungnam Medical Science / v.39, no.2, 2022 , pp. 153-160 More about this Journal
Abstract
Multicentric Castleman disease (MCD) is an uncommon systemic lymphoproliferative disorder that may cause multiple organ damage. Castleman disease-associated diffuse parenchymal lung disease (DPLD) has not been well studied. A 32-year-old man was referred to our hospital for progressive generalized weakness, light-headedness, and dyspnea on exertion for more than one year. Laboratory evaluations showed profound anemia, an elevated erythrocyte sedimentation rate, and an increased C-reactive protein level with polyclonal hypergammaglobulinemia. Chest radiography, computed tomography (CT), and positron emission tomography-CT scan demonstrated diffuse lung infiltration with multiple cystic lesions and multiple lymphadenopathy. In addition to these clinical laboratory findings, bone marrow, lung, and lymph node biopsies confirmed the diagnosis of idiopathic MCD (iMCD). Siltuximab, an interleukin-6 inhibitor, and glucocorticoid therapy were initiated. The patient has been tolerating the treatment well and had no disease progression or any complications in 4 years. Herein, we report this case of human herpesvirus-8-negative iMCD-associated DPLD accompanied by multiple cystic lesions, multiple lymphadenopathy, and polyclonal hypergammaglobulinemia with elevated immunoglobulin G (IgG) and IgG4 levels. We recommend a close evaluation of MCD in cases of DPLD with hypergammaglobulinemia.
Keywords
Immunoglobulin G4-related disease; Interstitial lung diseases; Langerhans-cell histiocytosis; Multicentric Castleman disease;
Citations & Related Records
연도 인용수 순위
  • Reference
1 van Rhee F, Voorhees P, Dispenzieri A, Fossa A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 2018;132:2115-24.
2 Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003;38:982-4.   DOI
3 Yamashita K, Haga H, Kobashi Y, Miyagawa-Hayashino A, Yoshizawa A, Manabe T. Lung involvement in IgG4-related lymphoplasmacytic vasculitis and interstitial fibrosis: report of 3 cases and review of the literature. Am J Surg Pathol 2008;32:1620-6.   DOI
4 Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol 2016;3:e163-75.   DOI
5 van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. Hematol Oncol Clin North Am 2018;32:89-106.   DOI
6 van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget 2015;6:30408-19.   DOI
7 Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am 2018;32:11-21.   DOI
8 Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020;72:7-19.   DOI
9 Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999;85:706-17.   DOI
10 Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, et al. The full spectrum of Castleman disease: 273 patients studied over 20 years. Br J Haematol 2018;180:206-16.   DOI
11 Palestro G, Turrini F, Pagano M, Chiusa L. Castleman's disease. Adv Clin Path 1999;3:11-22.
12 Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000;342:1969-78.   DOI
13 Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017;129:1646-57.   DOI
14 Shahidi H, Myers JL, Kvale PA. Castleman's disease. Mayo Clin Proc 1995;70:969-77.   DOI
15 Inoue D, Zen Y, Abo H, Gabata T, Demachi H, Kobayashi T, et al. Immunoglobulin G4-related lung disease: CT findings with pathologic correlations. Radiology 2009;251:260-70.   DOI
16 Mochizuki H, Kato M, Higuchi T, Koyamada R, Arai S, Okada S, et al. Overlap of IgG4-related disease and multicentric Castleman's disease in a patient with skin lesions. Intern Med 2017;56:1095-9.   DOI
17 Sato Y, Kojima M, Takata K, Morito T, Asaoku H, Takeuchi T, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol 2009;22:589-99.   DOI
18 Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9:822-30.   DOI
19 Takenaka K, Takada K, Kobayashi D, Moriguchi M, Harigai M, Miyasaka N. A case of IgG4-related disease with features of Mikulicz's disease, and retroperitoneal fibrosis and lymphadenopathy mimicking Castleman's disease. Mod Rheumatol 2011;21:410-4.   DOI
20 Huang H, Feng R, Li J, Song X, Li S, Xu K, et al. Castleman disease-associated diffuse parenchymal lung disease: A STROBEcompliant retrospective observational analysis of 22 cases in a tertiary Chinese hospital. Medicine (Baltimore)2017;96:e8173.   DOI